研究论文

新型嘌呤-8-酮衍生物的合成及抗肿瘤活性研究

  • 张自鹏 ,
  • 杨新颖 ,
  • 方浩
展开
  • 山东大学药学院 济南 250012

收稿日期: 2016-11-23

  修回日期: 2017-01-03

  网络出版日期: 2017-02-08

基金资助

国家自然科学基金面上(No.21672127)资助项目.

Synthesis and Antiproliferative Activity of Novel Purin-8-one Derivatives

  • Zhang Zipeng ,
  • Yang Xinying ,
  • Fang Hao
Expand
  • School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012

Received date: 2016-11-23

  Revised date: 2017-01-03

  Online published: 2017-02-08

Supported by

Project supported by the National Natural Science Foundation of China (No. 21672127).

摘要

以2,4-二氯-5-硝基嘧啶为起始原料,通过多步反应制备了一系列新型嘌呤-8-酮衍生物,并经1H NMR、13C NMR和HRMS结构确认.采用四甲基偶氮唑盐(MTT)法测定了目标化合物的体外抗肿瘤细胞增殖活性,结果表明:部分目标化合物具有较好的抗肿瘤细胞增殖活性,其中四个化合物抑制人子宫颈癌细胞(Hela)、人急性淋巴母细胞白血病细胞(MOLT-4)和白血病细胞(K562)的活性相当或优于阳性对照药R-Roscovitine.

本文引用格式

张自鹏 , 杨新颖 , 方浩 . 新型嘌呤-8-酮衍生物的合成及抗肿瘤活性研究[J]. 有机化学, 2017 , 37(6) : 1479 -1486 . DOI: 10.6023/cjoc201611031

Abstract

A series of novel purin-8-one derivatives were prepared with the starting materials of 2,4-dichloro-5-nitropyrimidine and followed by multi-step reactions. The structures of all target compounds were identified by 1H NMR, 13C NMR and HRMS. The preliminary biological evaluations were performed using thiazolyl blue tetrazolium bromide (MTT) method to test their antiproliferative activities against some tumor cell lines. The results suggested that some compounds exhibited good anti-proliferative activities against tumor cell lines. Especially, four compounds showed similar or better inhibitory activities against Hela, MOLT-4 and K562 tumor cell lines compared with R-roscovitine.

参考文献

[1] Legraverend, M.; Grierson, D. S. Bioorg. Med. Chem. 2006, 14, 3987.
[2] Zhang, J.-Y.; Wang, Q.-L.; Hou, X.-H.; Liu, H.-M. Chin. J. Org. Chem. 2015, 35, 1022 (in Chinese).(张京玉, 王清龙, 侯学会, 刘宏民, 有机化学, 2015, 35, 1022.)
[3] Di Virgilio, F.; Adinolfi, E. Oncogene 2017, 36, 293.
[4] Di Virgilio, F. Cancer Res. 2012, 72, 5441.
[5] Pui, C. H.; Jeha, S.; Kirkpatrick, P. Nat. Rev. Drug Discovery 2005, 4, 369.
[6] Denny, B. J.; Wheelhouse, R. T.; Stevens, M. F. G.; Tsang, L. L. H.; Slack, J. A. Biochemistry 1994, 33, 9045.
[7] Parker, W. B. Chem. Rev. 2009, 109, 2880.
[8] Sanford, D. S.; Wierda, W. G.; Burger, J. A.; Keating, M. J.; O'Brien, S. M. Clin. Lymphoma, Myeloma Leuk. 2015, 15, 385.
[9] Asghar, U.; Witkiewicz, A. K.; Turner, N. C.; Knudsen, E. S. Nat. Rev. Drug Discovery 2015, 14, 130.
[10] Wang J.-H.; Wang, Q.-D.; Dun Y.-Y.; Fang, H. Chem. J. Chin. Univ. 2014, 35, 1189 (in Chinese).(王军华, 王泉德, 顿艳艳, 方浩, 高等学校化学学报, 2014, 35, 1189.)
[11] Wang, J.-H.; Wang, Q.-D.; Zhang, L.-R.; Fang, H. Chin. J. Chem. 2013, 31, 1181.
[12] Zheng, W.; Thorne, N.; McKew, J. C. Drug Discovery Today 2013, 18, 1067.
[13] Andrews, D. M.; Jones, C. D.; Simpson, I.; Ward, R. A. WO 2009024824, 2009[Chem. Abstr. 2009, 150, 283068].

文章导航

/